Pemetrexed single agent in previously treated non-small cell lung cancer: A multi-institutional observational study

Lung Cancer

Volumn 60, Issue 2, 2008, Pages 240-245

  Bearz, Alessandra ^a   Garassino, Isabella ^b   Cavina, Raffaele ^b   Favaretto, Adolfo ^c   Boccalon, Massimo ^d   Talamini, Renato ^a   Berretta, Massimiliano ^a   Spazzapan, Simon ^a   Simonelli, Cecilia ^a   Santoro, Armando ^b   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d General Hospital of Pordenone   (Italy)

Author keywords

Chemotherapy; Non small cell lung cancer; Pemetrexed; Second line

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; GEMCITABINE; PEMETREXED; PLATINUM;

ADENOCARCINOMA; ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; INFORMATION PROCESSING; ITALY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; REGISTRATION; SENSORY DYSFUNCTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 42949170957     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.10.008     Document Type: Article

References (21)

1. Parkin D.M., Bray F.I., and Devessa S.S. Cancer burden for the year 2000: the global picture. Eur J Cancer 37 Suppl. 8 (2001) S4-S66
2. Parkin D.M., Bray F.I., Ferlay J., and Pisani P. Global cancer statistics, 2002. Ca Cancer J Clin 55 (2005) 74-108
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311 (1995) 899-908
4. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
5. Fossella F., DeVore R., Kerr R., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18 (2000) 2354-2362
6. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of Pemetrexed versus Docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. JCO 22 (2004) 1589-1596
7. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
8. Shih C., Habeck L.L., Mendelsohn L.G., Chen V.J., and Schultz R.M. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 38 (1998) 135-152
9. Schilsky R.L. Antimetabolites. In: Perry M.C. (Ed). The chemotherapy source book (1992), Williams & Wilkins, Baltimore (MD) 301-315
10. Solomon B., and Bunn Jr. P.A. Clinical activity of Pemetrexed: a multitargeted antifolate anticancer agent. Future Oncol 1 (2005) 733-746
11. Cancer Therapy Evaluation Program. 1998. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS.
12. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., and Rubinstein L. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
13. Fleiss J.L., Levin B., and Paik M.C. Statistical methods for rates and proportions. 3rd ed. (2003), Wiley and Sons Inc., Hoboken, USA
14. Kaplan E.L., and Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 53 (1958) 457-481
15. SAS Institute, Inc., Cary, NCI, 1999-2001
16. Pujol J.L., Paul S., Chouaki N., Peterson P., Moore P., Berry D.A., et al. Survival without Common Toxicity Criteria Grade 3/4 toxicity for Pemetrexed compared with Docetaxel in previously treated patients with advanced non small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2 (2007) 397-401
17. Weiss G.J., Langer C., Rosell R., Hanna N., Shepherd F., Einhorn L.H., et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small cell lung cancer. J Clin Oncol 24 (2006) 4405-4411
18. Weiss G.J., Rosell R., Fossella F., Perry M., Stahel R., barata F., et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 18 (2007) 453-460
19. Thun M.J., Lally C.A., Flannery J.T., Calle E.E., Flanders W.D., and Heath Jr. C.W. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 89 (1997) 1580-1586
20. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107 (2006) 1589-1596
21. Stabile L.P., Davis A.L., Gubish C.T., Hopkins T.M., Luketich J.D., Christie N., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological response to estrogen. Cancer Res 62 (2002) 2141-2150